Navigation Links
Favrille Reports First Quarter 2008 Financial Results
Date:5/8/2008

SAN DIEGO, May 8 /PRNewswire-FirstCall/ -- Favrille, Inc. (Nasdaq: FVRL), a biopharmaceutical company developing patient-specific, active immunotherapies for the treatment of cancer, today reported its financial results for the first quarter ended March 31, 2008. Net loss for the quarter was $10.5 million, or $0.25 per share, compared to $10.5 million, or $0.34 per share, for the same period in 2007.

(Logo: http://www.newscom.com/cgi-bin/prnh/20080404/LAF521LOGO)

"As we prepare for the unblinding of our Phase 3 data, we find ourselves at a critical inflection point," said John P. Longenecker, Ph.D., President and Chief Executive Officer of Favrille. "The outcome of this trial will not only define the future of our Company but, we believe, could ultimately change the course of treatment for non-Hodgkin's lymphoma patients. If successful, Specifid(TM) (mitumprotimut-T, formerly FavId(R)) would be a groundbreaking cancer therapy, the culmination of nearly a decade of collaboration between our employees, investors, clinical investigators, trial coordinators and patients."

First Quarter 2008 Financial Review

Research and development expense was approximately $8.1 million for the first quarter of 2008, compared to approximately $8.0 million for the same period in 2007. The increase is primarily due to additional operating expenses associated with Favrille's commercial-scale manufacturing facility, stock-based compensation, additional personnel and consulting and outside services to support the Company's Phase 3 registration trial of Specifid, offset by a decrease in manufacturing supplies related to the completion of patient enrollment in the Phase 3 trial and a decrease in cash bonus expense. Total stock-based compensation included in research and development expense was approximately $560,000 for the quarter, compared to approximately $400,000 for the f
'/>"/>

SOURCE Favrille, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. Favrille to Host Conference Call and Live Webcast to Discuss First Quarter 2008 Financial Results on May 8, 2008
2. Favrille Reports Fourth Quarter and Year End 2007 Financial Results
3. Favrille Announces $21.1 Million Registered Direct Offering
4. Favrille to Present at BIOCOM Investor Conference, Acumen BioFin Rodman & Renshaw Healthcare Conference and CIBC World Markets Healthcare Conference
5. Favrille to Host Conference Call and Live Webcast to Discuss Third Quarter 2007 Financial Results on October 25, 2007
6. Favrille to Present at BIO InvestorForum
7. Favrille to Present at AG Edwards Emerging Growth Conference and Wall Street Analyst Forum
8. Favrille CEO to Present at Bear Stearns Healthcare Conference
9. Favrille CEO to Present at NewsMakers in the Biotech Industry Investment Conference
10. Barr Reports First Quarter 2008 GAAP Earnings of $0.21 Per Share; Adjusted Earnings of $0.57 Per Share
11. BioCryst Reports First Quarter 2008 Financial Results and Clinical Update

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/6/2009)...RNewswire-FirstCall/ -- ,, 3Q09 Corporate Hi...M) E.U. Marketing Authorization to Astellas Pharma...cial readiness activities Expanded management tea... and Director, Commercial Operations Appointed Br...ommittee chairman , Upcoming 2009 Milestone...
(Date:11/6/2009)...FirstCall/ - Oncolytics Biotech Inc. (TSX:ONC, NAS...nounced updated results from a Phase II study of i...etastatic to the lung in a poster presentation at ... Meeting held in Miami Beach, Florida, from Novemb...A Phase II Study of Intravenous REOLYSIN (Wild-typ...
(Date:11/6/2009)...da for Arrowhead’s 2010 Personalized Medicin...ace on February 22-24, 2010 in Philadelphia, has b...l highlight key issues in forming partnerships and...es. , Minneapolis, MN (PR...rsquo;s 2010 Personalized Medicine Partnerships C...
(Date:11/5/2009)...RNewswire-FirstCall/ -- GenVec, Inc. (Nasdaq: GNV...third quarter ended September 30, 2009. GenVec rep... for the three months ended September 30, 2009 com...re) in the comparable quarter of 2008. For the nin...ss was $14.1 million ($0.15 per share), compared t...
Breaking Biology Technology:NeurogesX Reports Third Quarter 2009 Results 2NeurogesX Reports Third Quarter 2009 Results 3NeurogesX Reports Third Quarter 2009 Results 4NeurogesX Reports Third Quarter 2009 Results 5NeurogesX Reports Third Quarter 2009 Results 6NeurogesX Reports Third Quarter 2009 Results 7NeurogesX Reports Third Quarter 2009 Results 8NeurogesX Reports Third Quarter 2009 Results 9NeurogesX Reports Third Quarter 2009 Results 10Oncolytics Biotech(R) Inc. Collaborators Present Positive Phase II Sarcoma Trial Results at CTOS Annual Meeting 2Oncolytics Biotech(R) Inc. Collaborators Present Positive Phase II Sarcoma Trial Results at CTOS Annual Meeting 3Leaders in Biopharma and Molecular Diagnostics to Discuss Key Issues and Opportunities in Forming Partnerships at 2010 Personalized Medicine Partnerships Conference 2Leaders in Biopharma and Molecular Diagnostics to Discuss Key Issues and Opportunities in Forming Partnerships at 2010 Personalized Medicine Partnerships Conference 3GenVec Reports Third Quarter 2009 Financial Results 2GenVec Reports Third Quarter 2009 Financial Results 3GenVec Reports Third Quarter 2009 Financial Results 4GenVec Reports Third Quarter 2009 Financial Results 5GenVec Reports Third Quarter 2009 Financial Results 6
... Biosciences announces,an enhanced matching funds ...n in genomics. $1.75 million in matching funds is ... to each qualifying institution. The,Genomics Educ... streamlined,application process to help colleges ...ndergraduate students studying molecular biology a...
...n combats an,alarming rise in chronic diseases, th...rica (PhRMA) today released a new report on the ne...hat offer hope to millions,of patients., The repo...d,biotechnology companies - including several loca...tech medicines., Today,s report was released in M...
...ble Oils has reached a,key milestone in its effort...tunities for Montana farmers. The company received... a department of the Federal Drug,Administration, ...ot beef,cattle and growing swine up to 2 percent o... a by-product of camelina oil extraction., Sustai...
Other Biology Technology:New Report on 633 Biotechnology Medicines Under Development Released in Michigan 2New Report on 633 Biotechnology Medicines Under Development Released in Michigan 3Sustainable Oils Receives Regulatory Approval for Feeding Camelina Meal in Livestock Diets 2Sustainable Oils Receives Regulatory Approval for Feeding Camelina Meal in Livestock Diets 3
(Date:11/8/2009)... Ind. - Researchers at Purdue University have disc...fibers in spinal cord injuries using nano-spheres ...r an accident. , The synthetic "copolymer micell...in diameter, or roughly 100 times smaller than the...e been studying how to deliver drugs for cancer tr...
(Date:11/6/2009)...ration is now open for the Society of Intervention...gy (IO) Therapies" Webinar, which will provide the...treatment of liver tumors, kidney tumor ablation a...tion of physicians, scientists and allied health p...through pioneering advances in image-guided therap...
(Date:11/6/2009)...6 Auburn Hills, MI-based Law Enfor...talling its locker system and patent-pending Biome...Department of Health and Human Services, National ... The locker system will support the NIH,s entire p... nation,s medical research agency. The project is...
Breaking Biology News(10 mins):Findings show nanomedicine promising for treating spinal cord injuries 2Findings show nanomedicine promising for treating spinal cord injuries 3Society of Interventional Radiology hosts oncology therapies Webinar, offers resources 2EPA grant to University of Chicago for research on food allergy triggers 9332 1Rigel to Host Conference Call to Discuss Results of Its Phase 2b TASKi3 Clinical Trial of R788 in Rheumatoid Arthritis 52567 1Rigel to Host Conference Call to Discuss Results of Its Phase 2b TASKi3 Clinical Trial of R788 in Rheumatoid Arthritis 52567 2Study in this Week 26apos 3Bs Issue of Cell Finds Injected Growth Factor Spurs Heart Regeneration 52563 1Study in this Week 26apos 3Bs Issue of Cell Finds Injected Growth Factor Spurs Heart Regeneration 52563 2Study in this Week 26apos 3Bs Issue of Cell Finds Injected Growth Factor Spurs Heart Regeneration 52563 3
...hiny amber jewelry and a mucky Florida swamp have ...m that could be anywhere from 15 million to 130 mi...f Florida and the Museum of Natural History in Ber...quatic critters such as beetles and small crustace...the water from pine-like trees. Their findings are...
...ber 17, 2007. -- It all started as a graduate scho...ire to figure out why things live where they do, s...ive in different places? Ive been studying the dis...ears. So I even made this question the basis of my...s. , That burning desire led Neilson to develop t...
... the leading cause of death due to infectious dise...lion people are currently infected, and although m... occur. This paper by Denise Kirschner and colleag...ducts virtual clinical trials to examine the cause... (TNF) is a protein that facilitates cellcell comm...
Other Biology News:Scientists find how amber becomes death trap for watery creatures 2Scientists find how amber becomes death trap for watery creatures 3Neilson member of Nobel Prize-winning panel of scientists 2
CORNING CELLSTACK FILLINGD CAP, 33MM, BARBED FITTING, STERILE from Sigma-Aldrich
CORNING CELLSTACK FILLINGD CAP, 33MM, LUER LOCK FITTING, STERILE from Sigma-Aldrich
RNA Sample Loading Buffer from Sigma-Aldrich
...EM and harvested at the log phase of growth. In o...ells were fixed in acetone-methanol. The cells ar...e, with each wells surface specifically treated to...round staining. Each well is loaded with approxim...
Biology Products: